GLG News by Labor Relations and Union-Management Negotiation Experts (US)
Analysis of:
NACDS, FMI Urge Court to Oppose Proposed AWP Settlements that Would Penalize Retail Pharmacy and the Patients They Serve (nacds.org)
NACDS and FMI filed another brief in opposition to the controversial proposed First Databank settlement, although they overstate their arguments in a few places. I expect this battle to heat up over the next month as we get closer to the late December hearing about First Databank’s settlement. This...
Analysis of:
Scrutiny Grows of Drug Trials Abroad (online.wsj.com)
This article pertains to quality, accrual and safety, but in addition....
Analysis of:
McKesson Agrees To Settlement In Pricing Suits (online.wsj.com)
McKesson Corp (MCK) settled its pending class action suit for $351 million and set aside a further $143 million reserve for certain future claims. The settlement removes a source of uncertainty for McKesson, but also signals the beginning of the end for the Average Wholesale Price (AWP) benchmark. Average...
Analysis of:
For UAW, Aid Likely to Come With Strings (online.wsj.com)
1. Employment reductions in the U.S. auto assembly industry over the past three years have reduced the UAW-hourly represented workforce by roughly half. As a result, UAW monetary concessions at reasonable levels will not likely contribute substantially to solving the companies' short-rurnfinancial...
Analysis of:
Scientists recommend 'black box' for Avastin (www.fiercepharma.com)
The exact quote is " Avastin, could raise the risk of blood clots by about 12 percent."
Analysis of:
PROMACTA (Brand Name Drug) FDA approval 11/20/08 (www.accessdata.fda.gov)
An oral agent that can be used in patients with ITP that have become refractory to steroids, splenectomy and various immunologic manipulations.
Analysis of:
Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer (jco.ascopubs.org)
A VEGF inhibitor that appears to work well with chemo in non small cell lung carcinoma.
Analysis of:
Merck KGaA: Overall Survival in First-Line NSCLC Reaches 15 Months (www.drugs.com)
"New data from pivotal FLEX study reveal that patients treated with Erbitux who develop early skin rash show median overall survival of 15 months (p<0.001)" This is the trial that showed Erbitux + chemo prolonged survival minimally when compared to chemo alone. Now we know the ones who develop a...
Analysis of:
CVS joins generic drug price war (www.upi.com)
CVS Caremark (CVS) launched its new Health Savings Pass, which allows customers to buy 90 day supplies of over 400 generics for $9.99 (after paying an enrollment fee of $10). The new program sounds like a logical pre-emptive strike against anticipated share losses. Translation: an old-fashioned, race-to-the-bottom...
Analysis of:
Roche Says Tarceva Data Promising (online.wsj.com)
Tarceva can maintain a remission in non small cell lung cancer after initial therapy with other agents. Just like Lilly's Alimta
Previous Page : 1 2 3 4 5 6 7 8 9 10 11 Next11 to 20 of 672
Most Popular Legal, Economic & Regulatory Affairs News
Expert Analyses | Source Article
www.cafc.uscourts.gov
Address by Chief Judge Paul Michel to the FTC Commission on Evolving IP Marketplace
www.washingtonpost.com
Dr. Leavitt's Scary Diagnosis
www.biocycle.net
The State of Garbage in America
atlanta.bizjournals.com
Financial Stress Likely at Charter
online.wsj.com
Funding Senior Living In An Economic Downturn
January 2, 2009
If you think health care and Medicare are problems, consider long-term care and Medicaid.
December 31, 2008
Politics aside, there is no perfect solution to the auto industry problem.
December 30, 2008
Initial Steps Local Franchising Authorities Will Take toward a Charter Bankruptcy
December 28, 2008
US Car Industry doesn't Need Restructruting As Much as it Needs to Get Rid of UAW
December 28, 2008
Federal Trade Commision: Patent Reform, Part II